^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CL-387785

    i
    Other names: WAY-EKI 785, CL-387785, EKI-785, CL 387785
    Company:
    Pfizer
    Drug class:
    EGFR inhibitor
    Related drugs:
    19d
    Targeted Induction of Cancer Cell Necroptosis Potentiates Anti-PD-1 Immunotherapy via CD80 Activation. (PubMed, Int J Biol Sci)
    In conclusion, our findings indicate that CL-387785 induces necroptosis in tumor cells via the TRADD/RIPK1/NF-κB/CD80 signaling pathway, thereby sensitizing tumors to anti-PD-1 therapy. These results suggest that CL-387785 is a promising candidate for increasing tumor immunotherapy efficacy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • RIPK1 (Receptor Interacting Serine/Threonine Kinase 1) • CD80 (CD80 Molecule)
    |
    CL-387785
    over2years
    Exosomes from PYCR1 knockdown bone marrow mesenchymal stem inhibits aerobic glycolysis and the growth of bladder cancer cells via regulation of the EGFR/PI3K/AKT pathway. (PubMed, Int J Oncol)
    Exo‑si‑PYCR1 blocked xenograft tumor growth and had good biocompatibility. Briefly, PYCR1 knocking loaded by BMSC‑derived Exos suppressed aerobic glycolysis and BC growth via the PI3K/AKT pathway by binding to EGFR.
    Journal
    |
    PRO-C3 (Pyrroline-5-carboxylate reductase)
    |
    CL-387785